Together these results demonstrate the functionality of the SEMA7A pathway in a significant fraction of ACC tumors and the significantly poor prognosis of patients with high SEMA7A expression and SEMA7A pathway activation. This evidence concerns the gene SEMA7A and adrenal cortex carcinoma.